Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes, Obesity and Metabolism

Volumn 16, Issue 4, 2014, Pages 366-375

  Evans, M ^a   Wolden, M ^b   Gundgaard, J ^b   Chubb, B ^c   Christensen, T ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk Ltd   (United Kingdom)

Author keywords

Cost effectiveness; Insulin analogues; Insulin therapy; Pharmaco economics; Type 2 diabetes

Indexed keywords

INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLARGINE; INSULIN; LONG ACTING INSULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; NATIONAL HEALTH SERVICE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TEST STRIP; UNITED KINGDOM; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; ECONOMICS; FEMALE; HYPOGLYCEMIA; MALE; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84895082258     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12250     Document Type: Article

References (56)

1. Diabetes UK. Diabetes in the UK 2012, Key statistics on diabetes. Available from URL: http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf. Accessed 5 March 2013.
2. U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-1136.
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205-218.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
5. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
6. Fonseca V. Defining and characterising progression of type 2 diabetes. Br J Diabetes Vasc Dis. 2008; 8: S3.
7. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
8. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011; 27(Suppl. 3): 13-20.
9. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007; 68: 10-15.
10. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
11. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008; 24: 87-92.
12. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012; 29: 855-862.
13. Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007; 23: 441-454.
14. National Institute for Health and Clinical Excellence. Clinical Guideline 87: Type 2 diabetes: the management of type 2 diabetes 2009. Available from URL: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf. Accessed 24 November 2012.
15. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
16. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
17. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
18. TM LOW VOLUME trial. Diabetes Care 2013; 36: 2536-2542.
19. Onishi Y, Woo Park S, Jib Yoo S, Clauson P, Tamer SC, Iwamoto Y. Insulin degludec improves glycemic control in insulin-naïve patients with type 2 diabetes: results of a randomised pan-Asian trial. Poster 1059. Presented at the American Diabetes Association 72nd Annual Scientific Sessions, Philadelphia 8-12 June 2012.
20. Zinman B, Philis-Tsimikas A, Cariou B et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
21. Ratner R, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
22. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006; 21: 402-408.
23. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2008. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 5 March 2013.
24. National Institute for Health and Clinical Excellence. Measuring effectiveness and cost-effectiveness: The QALY. 2010. Available from URL: http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. Accessed 5 March 2013.
25. Food and Drug Administration. Guidance for industry. diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention - Draft Guidance. February 2008. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf. Accessed 10 March 2012.
26. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
27. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20: 1016-1021.
28. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications 2006; 20: 402-408.
29. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697-703.
30. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.
31. Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009; 32: 1196-1198.
32. Heller SR. Hypoglycaemia: its pathophysiology in insulin treated diabetes and hypoglycaemia unawareness. Br J Diabetes Vasc Dis. 2011; 11: 6-9.
33. Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014; 31: 92-101.
34. Sanofi-Aventis. Lantus (insulin glargine): Structure titration to target fasting glucose. Available from URL: http://www.lantus.com/hcp/dosing-titration/titration-guide.aspx. Accessed 4 June 2013.
35. Meneghini L, Miranda-Palma B. Insulin degludec: a novel ultra-long-acting basal insulin for use in type 1 and type 2 diabetes. Expert Rev Endocrinol Metab 2012; 7: 9-14.
36. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 7: 27.
37. Freemantle N, Evans M, Christensen T, Wolden ML, Bjorner JB. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 564-571.
38. Evans M, Khunti K, Mamdani M et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013; 11: 90.
39. ®) Summary of product characteristics. 2013.
40. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
41. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011; 12: 219-230.
42. Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality of life (HRQoL): a time trade-off survey. J Med Econ 2013; 16: 1357-1365.
43. Philis-Tsimikas A, Brod M, Niemeyer M, Franciso AMO, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or stepwise titration (BEGIN™: ONCE SIMPLE). Adv Ther 2013; 30: 607-622.
44. Farmer A, Wade A, French DP, Goyder E, Kinmonth AL, Neil A. The DiGEM trial protocol--a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes [ISRCTN47464659]. BMC Fam Pract 2005; 6: 25.
45. Farmer A, Wade A, Goyder E et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 132.
46. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; 336: 1177-1180.
47. Saramago P, Manca A, Sutton AJ. Deriving input parameters for cost-effectiveness modeling: taxonomy of data types and approaches to their statistical synthesis. Value Health 2012; 15: 639-649.
48. European Medicines Agency. Tresiba EPAR: public assessment report. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002498/WC500139010.pdf. Accessed 25 April 2013.
49. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012; 15: 77-86.
50. ISD Scotland. Scottish Ambulance Service, expenditure and statistics, by board area, 2010-2011. Available from URL: http://www.isdscotland.org/Health-Topics/Finance/Publications/2011-11-29/Costs_R910_2011.xls. Accessed 6 September 2012.
51. Department of Health. Payment by results tariffs. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_124356. Accessed 11 January 2013.
52. Personal Social Services Research Unit. Unit costs of health and social care 2011. Available from URL: http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf. Accessed 14 November 2012.
53. Dornhorst A, Luddeke HJ, Sreenan S et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61: 523-528.
54. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009; 12: 281-290.
55. Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180.
56. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-1534.